BaseLaunch is top European accelerator
Healthcare Accelerator BaseLaunch, which is operated by the location promotion organization BaselArea.swiss, is among the leading accelerators of its kind in Europe, according to a media report. BaseLaunch is the only Swiss Healthcare Accelerator to feature.
“Sifted”, an online magazine supported by the “Financial Times”, has analyzed the leading Healthcare Accelerators in Europe. It aimed to find out which accelerators provide healthcare startups with the best opportunities for development and to find investment.
The list of the best European accelerators that specialize in healthcare is very short, with “Sifted” naming just eleven institutions. BaseLaunch, which is operated by BaselArea.swiss, is the only Swiss institution to feature. According to the article, BaseLaunch is the rarest type of accelerator – it provides investment and support without asking for equity in return. Instead, big industry funding comes from companies like Novartis, Roche, Roivant Sciences, Johnson & Johnson, Pfizer and KPMG.
Basel is already world-famous in life sciences, but BaseLaunch is supporting even more startups making exciting developments. It offers them business development and legal services, as well as fully equipped labs. Furthermore, grants are available up to 250,000 Swiss francs per company by the end of the 15-month programme. BaseLaunch looks for companies innovating in the therapeutics space, medtech and diagnostics.
In Germany, the only country in which “Sifted” names several high-ranking healthcare accelerators, there are three institutions listed. Like Switzerland, the other countries featured – Great Britain, Sweden, the Netherlands, Spain, Italy, Denmark and Hungary – have only one accelerator included in the ranking.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More